Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Gemcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 2/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.89 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.89 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.89 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.55 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.55 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.45 |
| ▸ | ALB | P02768 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | CDA | P32320 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine SCHEMBL350020 | 0.97 | PDE3A (0.91) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL17978348 | 0.97 | PDE3A (0.91) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL285130 | 0.97 | PDE3A (0.91) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL348218 | 0.97 | PDE3A (0.91) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL28334969 | 0.96 | PDE3A (0.89) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL249738 | 0.94 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL19526092 | 0.94 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6369622 | 0.94 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL20827751 | 0.94 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL17858716 | 0.94 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014086942-A1 | CONJUGATES OF THE B-SUBUNIT OF SHIGA TOXIN FOR USE AS CONTRASTING AGENTS FOR IMAGING AND THERAPY | INSTITUT CURIE (FR) | 2014-06-12 | — | — | WO | claimed |
| EP-2740491-A1 | Conjugates of the B-subunit of shiga toxin for use as contrasting agents for imaging and therapy | Institut Curie (FR) | 2014-06-11 | — | — | EP | claimed |
| US-11845938-B2 | Aptamer compositions and the use thereof | CITY OF HOPE (US) | 2023-12-19 | — | — | US | disclosed |
| US-11261449-B2 | Anti-cancer RNA aptamers | CITY OF HOPE (US) | 2022-03-01 | — | — | US | disclosed |
| US-20200354721-A1 | ANTI-CANCER RNA APTAMERS | APTERNA LTD (GB) | 2020-11-12 | — | — | US | disclosed |
| EP-3172218-B1 | PROCESS FOR THE PREPARATION OF GEMCITABINE-[PHENYL(BENZOXY-L-ALANINYL)] PHOSPHATE | NuCana plc (GB) | 2020-10-21 | — | — | EP | disclosed |
| US-20200299696-A1 | APTAMER COMPOSITIONS AND THE USE THEREOF | CITY OF HOPE | 2020-09-24 | — | — | US | disclosed |
| US-10550394-B2 | Anti-cancer RNA aptamers | CITY OF HOPE (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180087053-A1 | ANTI-CANCER RNA APTAMERS | CITY OF HOPE | 2018-03-29 | — | — | US | disclosed |
| US-9834577-B2 | Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate | LAURUS LABS LIMITED (IN) | 2017-12-05 | — | — | US | disclosed |
| WO-2017173247-A1 | APTAMER COMPOSITIONS AND THE USE THEREOF | CITY OF HOPE (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170166602-A1 | PROCESS FOR THE PREPARATION OF GEMCITABINE-[PHENYL(BENZOXY-L-ALANINYL)] PHOSPHATE | NUCANA BIOMED LIMITED (GB) | 2017-06-15 | — | — | US | disclosed |
| EP-3172218-A1 | PROCESS FOR THE PREPARATION OF GEMCITABINE-[PHENYL(BENZOXY-L-ALANINYL)]PHOSPHATE | NuCana BioMed Limited (GB) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016161165-A1 | ANTI-CANCER RNA APTAMERS | CITY OF HOPE (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016012781-A1 | PROCESS FOR THE PREPARATION OF GEMCITABINE-[PHENYL(BENZOXY-L-ALANINYL)] PHOSPHATE | NUCANA BIOMED LIMITED (GB) | 2016-01-28 | — | — | WO | disclosed |
| WO-2014086942-A1 | CONJUGATES OF THE B-SUBUNIT OF SHIGA TOXIN FOR USE AS CONTRASTING AGENTS FOR IMAGING AND THERAPY | INSTITUT CURIE (FR) | 2014-06-12 | — | — | WO | disclosed |
| EP-2740491-A1 | Conjugates of the B-subunit of shiga toxin for use as contrasting agents for imaging and therapy | Institut Curie (FR) | 2014-06-11 | — | — | EP | disclosed |
| US-20130131008-A1 | LIPOPHILIC MONOPHOSPHORYLATED DERIVATIVES AND NANOPARTICLES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2009053654-A2 | GEMCITABINE PHOSPHOESTER PRODRUGS AS ANTICANCER AGENTS | HOSPICES CIVILS DE LYON (FR) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131008-A1 | LIPOPHILIC MONOPHOSPHORYLATED DERIVATIVES AND NANOPARTICLES | LIPA, PNLIP, TYMP | POLA1 390/4885PDE3A 2754/4885PDE4D 3473/4885 |
| US-20170166602-A1 | PROCESS FOR THE PREPARATION OF GEMCITABINE-[PHENYL(BENZOXY-L-ALANINYL)] PHOSPHATE | TYMP, PNP, PHYKPL | POLA1 225/4885PDE3A 2224/4885PDE4D 2069/4885 |
| US-11845938-B2 | Aptamer compositions and the use thereof | RNGTT, PABPC4, DNTT | POLA1 1094/4885PDE3A 2635/4885PDE4D 2094/4885 |
| US-20200299696-A1 | APTAMER COMPOSITIONS AND THE USE THEREOF | RNGTT, PABPC4, DNTT | POLA1 1094/4885PDE3A 2635/4885PDE4D 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.